Polfa Tarchomin pedals hard to catch Bioton

Currently the gap between the two is enormous, with each holding 2% and 24% respectively in a market worth an annual zł.500 million. "We are considering entering the European and Arab markets," said Dariusz Sobczak, president of Polfa Tarchomin. "Which, at the earliest, will be possible next year." Until recently the company was only producing animal insulin which, while more expensive to produce, is an area of the market it enjoys a substantial share. Not only in Poland, but also in Belarus and Vietnam. The company is also planning to continue its expansion in China with antibiotics, which currently accounts for 1.5% of its exports. "We want to double this result in 2007," said Sobczak. "We cooperate with a large Chinese company, which handles among others distribution." The company is also planning new investments, including a zł.120-130 million pill production facility which is to operational by the start of 2009. (Puls Biznesu, pp. 1, 6) M.M.